Pharmaceuticals and Healthcare
We advise pharmaceutical companies, biotechnology firms, medical device manufacturers, digital health platforms, and investors on high-stakes disputes, regulatory enforcement, and strategic advisory matters across India’s healthcare and life sciences ecosystem. Our practice combines deep sectoral knowledge with strong advocacy in commercial and regulatory forums.
We represent clients in complex international arbitrations involving joint venture breakdowns, exclusive distribution disputes, and licensing termination, including matters governed by the rules of leading arbitral institutions. Our team acts in litigation and enforcement proceedings concerning product liability, manufacturing and supply chain disputes, regulatory non-compliance, and public procurement conflicts.
We advise across the entire product lifecycle—from clinical trial structuring and R&D agreements to marketing approvals, post-market surveillance, and pharmacovigilance. Our work includes securing approvals from the Central Drugs Standard Control Organization (CDSCO), advising on regulatory strategy under the Drugs and Cosmetics Act, and representing clients in investigations, licensing disputes, and compliance proceedings.
We assist in navigating pricing and market access issues under the Drugs (Prices Control) Order (DPCO), including disputes related to price caps, inclusion in essential drug lists, and tender-based procurement. Our team frequently advises on cost-containment measures and regulatory challenges affecting commercial outcomes.
We also support global and domestic players in structuring cross-border collaborations, licensing arrangements, technology transfers, and foreign direct investments in the pharma and med-tech space. Our experience includes disputes arising out of strategic alliances, supply and manufacturing agreements, and post-deal indemnity claims.
In the digital health and med-tech domain, we advise on regulatory frameworks for telemedicine, AI-driven diagnostics, electronic health records (EHRs), and digital therapeutics, including compliance with the Digital Personal Data Protection Act, 2023 (DPDPA) and overlapping healthcare privacy standards.
Our defence practice includes product liability claims, medical negligence litigation, and regulatory enforcement actions involving adverse event reporting, recall obligations, and consumer protection. We also advise on competition law issues such as distribution exclusivity, pricing practices, and potential abuse of market position in the pharmaceutical supply chain.
With an integrated offering across contentious, regulatory, and strategic issues, we enable life sciences and healthcare clients to operate with confidence across evolving legal regimes and high-risk commercial environments